Envoya is an innovative drug delivery company specializing in gene therapy delivery using cutting-edge nanoparticles fabricated from non-lipid FDA approved polymers. Unlike traditional gene therapy delivery systems, Envoya's nanoparticles are uniquely designed to be able to encapsulate large genetic payloads and be non-immunogenic, minimizing the risk of adverse immune responses, enabling multiple dosing providing flexibility and efficiency in long-term treatment plans, and making them suitable for a wide range of gene therapy applications. Additionally, Envoya’s delivery system is client-suited and customizable, allowing for personalized therapy solutions. With a commitment to pioneering advancements in gene therapy, Envoya is at the forefront of delivering client tailored, effective, and safe therapeutic solutions.